Dear Dr. Chang:

The Food and Drug Administration (FDA, the Agency) has investigated allegations that you failed to fulfill the responsibilities of a clinical investigator for studies utilizing unlicensed biological investigational new drugs. During the period from August 22 to November 16, 2001, Ms. Lisa Oakes, an investigator from the FDA Detroit District Office, visited the University of Michigan to inspect the records relating to your studies of investigational autologous activated cells and gene transfer vectors. This inspection was conducted as part of FDA's Bioresearch Monitoring Program that includes inspections designed to review the conduct of research involving investigational drugs.

At your option, you chose not to participate in a discussion of the findings at the end of the inspection. The Form FDA 483, "List of Inspectional Observations," was sent by certified mail to you and your attorney. Your attorney responded on your behalf in a letter to FDA dated January 11, 2002.

Based on our evaluation of information obtained by the Agency, we believe that you have repeatedly or deliberately violated regulations governing the proper conduct of clinical studies involving investigational new drugs, as published under Title 21, Code of Federal Regulations (CFR), Parts 312, 50, and 56. These regulations are available at http://www.access.gpo.gov/nara/cfr/index.html.

Records from the following studies were reviewed during the inspection:

Protocol 1990-489: "Adoptive-Cellular Therapy of Cancer with Tumor-Primed Anti-CD3 Activated Lymphocytes;"
Protocol 1995-243: "Adoptive Immunotherapy of Cancer with Activated Lymph Node Cells Primed \textit{In Vivo} with Autologous Tumor Cells Transduced with the GM-CSF Gene;"

Protocol 1995-318: "Study of Tumor Infiltrating Lymphocytes Derived \textit{In Vivo} —— Gene Modified Tumors in the Adoptive Immunotherapy of Melanoma;" and

Protocol 1997-004: "A Phase I Trial Assessing Autologous, Tumor-Pulsed Dendritic Cells That Have Been Activated by GM-CSF and IL-4 as a Tumor Vaccine in Patients with Advanced Cancer."

This letter provides you with written notice of the matters under complaint and initiates an administrative proceeding, described below, to determine whether you should be disqualified from receiving investigational articles as set forth under 21 CFR § 312.70.

A listing of the violations follows. The applicable provisions of the CFR are cited for each violation.

1. **You failed to fulfill the general responsibilities of investigators.**
   
   [21 CFR § 312.60 and Part 50].

   An Investigator is responsible for ensuring that an investigation is conducted according to the signed investigational statement, the investigational plan, and applicable regulations; for protecting the rights, safety, and welfare of subjects under the investigator's care; and, for the control of drugs under investigation. On March 14, 1990, and on several other occasions thereafter, you signed an FDA Form 1572, Statement of Investigator, in which you agreed to conduct the studies in accordance with the protocol and applicable regulations.

   Our investigation revealed that you did not fulfill your obligations as the clinical investigator in the use of investigational new drugs because you failed to adequately protect the rights, safety, and welfare of subjects.

   A. You permitted subjects who failed to meet the eligibility criteria to participate in the clinical trials. Subjects were administered the investigational products even though they should have been excluded according to the requirements established in the protocols.

   i. Protocol 1990-489 excludes patients with a prior second malignancy.

   a. Subject ——— was not eligible to participate in study 1990-489 because the subject had a history of prostate cancer.
b. Subject ——— was not eligible to participate in study 1990-489 because the subject had a history of colon cancer.

In your response letter dated January 11, 2002, your attorney acknowledges that these subjects were enrolled in violation of the protocol requirements. The response letter explains that you considered these prior second malignancies to be “cured.” However, the protocol did not permit discretion regarding the enrollment of subjects with any prior second malignancy.

ii. Protocol 1997-064 excludes patients with a history of corticosteroid use in the four weeks preceding entry into the study and states “patients who require corticosteroids are not eligible for this study.” Subject ——— was receiving corticosteroids due to seizures caused by brain metastases. In your letter dated 5/14/98 to the subject’s doctors, you state “currently, because she is on high doses of steroids, she is ineligible for our protocol. The steroids are too much of an immunosuppressive agent to consider the vaccine trials to have any potential effectiveness.” On 5/15/98, another physician advised Subject ——— that she had the option of your experimental tumor vaccine that would require the subject to be off steroids for three to four weeks, and that this would require withdrawing from a standard treatment in order to receive an experimental treatment. The subject and family agreed to begin a gradual reduction in the dose of corticosteroids that would end in 30 days. However, this subject was administered the investigational activated cells on 6/23/98, less than four weeks past the end of corticosteroid use, in violation of the protocol requirement.

In your response letter dated January 11, 2002, your attorney explains that you “believed [subject ———] was not a good candidate for the protocol due to her requirement for steroids for her brain metastases” yet you enrolled her anyway. You claim that the subject “remained stable for a period of time,” yet this subject died on ——— just eight days after you administered the test article. As noted above, you were aware and had stated in writing that immunosuppressed subjects would likely be unable to produce an immune response yet you still enrolled this ineligible subject, exposing her to the unknown risks of an investigational drug without the expectation of a benefit.

B. You failed to adequately protect the rights and safety of subjects because you failed to obtain informed consent in accordance with the provisions of 21 CFR Part 50. You conducted study-related procedures required by
protocol 1990-489 before subjects signed the informed consent document. The protocol scheme expressly required that "Surgical tumor retrieval" would occur after "Patient entry." (Protocol 1990-489 at 1). Section 7.0 of the protocol requires "eligible patients will have removal of accessible sites of tumor." Protocol section 7.1 requires "Surgery - Patients will undergo surgery for retrieval of easily accessible tumor." The following examples are a non-exclusive list of violative conduct.

i. Subject —— underwent an exploratory laparotomy with excision of retroperitoneal lymph nodes on 3/29/98. Medical records document that you discussed the study with this subject two weeks before the surgery, during which time the subject needed to get clearance from his health plan "for us to initiate therapy accordingly." According to your notes, you also informed the subject that the study "would entail retrieval of some tumor from the retroperitoneum in order for us to make a vaccine of his tumor." Your records also document that you considered this subject to have been enrolled in the "Phase II" study. The subject did not sign the consent form until 5/14/96.

ii. Subject ——— underwent a resection of tumor "harvested for adjuvant immunotherapy" from the left renal bed. Medical records document that before the surgery, you discussed with the subject that you would perform the "laparotomy for excision of recurrent tumor in her left renal bed which we could utilize for the vaccine protocol." You did not obtain a signed consent form from the subject before you harvested the tumor tissue for the study.

In your response letter dated January 11, 2002, your attorney admits that you did not obtain the signed informed consent from Subject ——— because "her disease then progressed and she became ineligible." Nevertheless, her medical records document that you considered her to have been enrolled in the "Phase II" protocol.

iii. Subject ——— underwent a right nephrectomy with tumor harvest on 4/12/99. Medical records document that on 3/31/99, the subject was informed that "...our adoptive therapy protocol...would require him to undergo a nephrectomy for tumor harvest." The hospital discharge report dated 4/15/99 following the nephrectomy states the subject "...was entered into the tumor harvest and IL-2 [interleukin-2] protocol per Dr. Chang." The subject did not sign the consent form until 5/18/99.
iv. Subject underwent a left radical nephrectomy and left hepatic wedge resection on 11/19/99. Medical records document that the subject "will be scheduled for nephrectomy so that we can make a tumor vaccine from her own tumor" and "the patient elected to proceed with radical nephrectomy and [sic] followed by autologous tumor vaccine plus interleukin-2." You did not obtain the signed informed consent from the subject until 1/4/00.

In your response letter dated January 11, 2002, your attorney explains that you "believed that it was sufficient to obtain informed consent prior to vaccination, even if a tumor removed or debulked previously had been preserved in anticipation of the patient's participation." In each of the examples listed above, the subjects were informed that surgery to remove tumor tissue was required to participate in the study. Moreover, your explanation conflicts with the express language of the approved protocol. Subjects did not sign the informed consent document that described the potential risks of the study until after they had experienced invasive surgery that is not considered to be the standard of care proven to benefit patients with metastatic renal cell carcinoma. Although you claim that in some cases "nephrectomy was performed for therapeutic purposes," nephrectomy is not the current standard of care for metastatic renal cell carcinoma. The position of your institution is that...

...nephrectomy in patients with metastatic renal cell carcinoma was not the standard of care in 1991 – or now—as there is little or no evidence that the procedure enhances either survival or quality of life in such patients.  

2. You failed to ensure that an investigation is conducted according to the investigational plan. [21 CFR § 312.60].

A. You did not perform protocol-required tests to determine whether subjects were eligible to participate in the studies. The following examples are a non-exclusive list of violative conduct.

i. Protocol 1990-489 section 5.0 requires several tests to determine whether potential subjects met the protocol inclusion criteria and did not have conditions that excluded them from the study. These criteria were to be prospectively evaluated to determine whether subjects were eligible to proceed to "have removal of accessible sites of tumor" according to protocol section 7.0. There is no...

documentation that you performed the following required tests to establish that the following subjects were eligible for the study before they underwent surgery:

a. CT scan of the head to exclude brain metastasis (exclusion criterion, section 5.2.e) -- Subjects and

In your response letter dated January 11, 2002, your attorney states that Subject did not have a brain CT scan until more than two months after you administered the investigational product. Your response also admits that you have no documentation to verify that screening CT scans were performed for Subjects and

b. HIV test (exclusion criterion, section 5.2.j) -- Subjects

In your response letter dated January 11, 2002, your attorney acknowledges that you did not perform these tests because you no longer believed HIV testing "to be useful as eligibility requirements." Nevertheless, the response letter states that you "now recognize" that the protocol should have been formally amended to seek approval to eliminate this test.

ii. Protocol 1990-489 section 9.1 lists several procedures that must be performed as part of the pretreatment evaluation of subjects before administration of the activated cells and interleukin-2 (IL-2). There is no documentation that you performed the following required evaluations:

a. Urinalysis (pretreatment evaluation, section 9.1.d) -- Subject

b. Hepatitis B surface antigen (HbsAg) (pretreatment evaluation, section 9.1.e) -- Subjects and

c. HTLV-III antigen (pretreatment evaluation, section 9.1.e) -- Subjects

d. Head CT scan (pretreatment evaluation, section 9.1.i) -- Subjects
e. Bone scan (pretreatment evaluation, section 9.1.j) – Subjects

f. Pregnancy test (pretreatment evaluation, section 9.1.k) – Subject

In your response letter dated January 11, 2002, your attorney acknowledges that either these tests were not performed or that you cannot locate documentation that the tests were performed.

Further, as before, your attorney explains that, in your medical judgment, you no longer believed HIV testing, bone scans, and HbsAG tests “to be useful as eligibility requirements.”

iii. Protocol 1995-243 section 5.0 requires several tests to determine that potential subjects meet the protocol inclusion criteria, and do not have conditions that exclude them from the study. In addition, section 8.1 lists tests required as part of the “pretreatment patient evaluation.” There is no documentation that you performed the required head CT scan, HTLV III antigen test, and pregnancy test for Subject

In your response letter dated January 11, 2002, your attorney acknowledges that the HTLV III antigen and pregnancy tests were not performed, and that you cannot locate the documentation that the brain CT test was conducted. The response also states that when you wrote the protocol, you “included the list of tests that is set forth in the protocol as a checklist of testing to be performed when clinically indicated” (emphasis added).

Your responses to these issues indicate that you believe that you have the “flexibility” to perform only those screening tests you deem important on a subject-by-subject basis. To the contrary, the approved protocols clearly require you to perform all specified tests to protect the safety and welfare of the study subjects.

B. You administered additional courses of the investigational products to some subjects even though their conditions did not permit retreatment according to the protocols.

i. Protocol 1990-489 section 9.2 requires that “patients that recur at any site will be considered as failures of that treatment arm.” In addition, section 9.2 of the protocol permits “retreatment (a second cycle) within the following month” only “if a tumor response (PR
[partial response] or CR [complete response]) is evident by 2 months post treatment." Section 10 of the protocol defines these terms:

10.1 Complete tumor response (CR) is defined as disappearance of all signs, symptoms, biochemical, and radiographic evidence of tumor.

10.2 Partial response (PR) is defined as a reduction of all measurable tumor lesions by — of the product of the two greatest perpendicular diameters (sum of all evaluable tumors), without the appearance of new tumor lesions or the concurrent progression of any previously defined lesions.

You failed to follow the protocol when you retreated the subjects listed below. The following is a non-exclusive list of violative conduct.

a. Subject —— was administered a second cycle of activated cells and IL-2 even though the subject had "slight progression of his pulmonary disease, as well as progressive disease in his retroperitoneum."

b. Subject —— was administered a third cycle of IL-2 even though a CT scan demonstrated that her disease had progressed. A left para-aortic node had grown to 19 x 14 mm from the previous scan when it measured 12 x 14 mm. A preclaval lymph node had also grown to 34 x 14 mm from 29 x 2 mm.

c. Subject —— was administered additional cycles of the test article after CT scan showed signs of progressive disease in mediastinal and bilateral axillary lymph nodes. The pulmonary tumor nodules and bilateral inguinal lymph nodes had not diminished in size.

d. Subject —— was administered a third cycle of IL-2 in December 1999 even though the subject had evidence of possible new nodules in the spleen and lung, indicating progressive disease.

In your response letter dated January 11, 2002, your attorney acknowledges that Subject —— was known "to have slight progression in size of para-aortic, and precaval nodal masses," and claims that Subject —— had stable disease. Your response also claims that the splenic lesions of Subject —— were too
small to be classified as metastases, but offers no explanation about this subject’s possible new tumors in the lung. Your response also explains “retreatment for stable disease or minor response was not excluded by the protocol.”

These explanations are unacceptable because the protocol requirement is clear -- the protocol specifically permitted retreatment only in the case of partial or complete responses, defined by shrinkage of tumors. None of the subjects listed above demonstrated a reduction in the size of their tumors, and, therefore, they were not eligible to be retreated in the study.

ii. Protocol 1995-318 section 10.3.2 requires that subjects “will be taken off study immediately” if subjects develop progressive disease “requiring the institution of alternative treatments such as radiation, surgery or other drug therapy.” Following the first injection of the investigational vector, Subject —— was diagnosed with a new tumor metastasis in the right ulna that required radiation treatments beginning on 8/2/99, yet you administered a third injection of the investigational vector on 8/11/99. According to the protocol requirement, Subject —— should have been immediately removed from the study.

In your response letter dated January 11, 2002, your attorney explains that you did not consider the forearm pain to be indicate of progressive disease, and that, in your opinion, “the lesion in this patient’s forearm must have been there at the start of treatment because the patient started to complain of pain only two weeks after the initiation of intratumoral injection...” However, at the beginning of this study, the subject was not experiencing pain in the forearm, yet, as you state, “the patient started to complain of pain only two weeks after the initiation of intratumoral injection of the experimental gene...” According to protocol section 11.1.4, progressive disease includes “worsening of tumor-related symptoms [sic] clinically significant by physician.” For this subject, the tumor-related symptoms were significant enough that the subject was referred for radiation treatments.

In addition, your attorney explains that “having to institute palliative radiation during the course of the study was not a specified indication to stop the treatment under the protocol.” We disagree. Protocol section 10.3 requires that subjects will be taken off study immediately if the subject develops progressive disease that
requires alternative treatments such as radiation. The use of alternate treatments confounds the assessment of safety or efficacy of investigational drugs.

C. You failed to follow the protocol regarding the management of toxicity related to the infusion of IL-2. Protocol 1990-489 section 8.4 requires that IL-2 dose modifications would be “related to individual organ toxicity” according to protocol Table 1. Table 1 defines the specific circumstances in which the IL-2 doses “which are held will be restarted” if the specific toxicity resolves to the next acceptable lower level” [emphasis added]. If any Grade 4 adverse events occurred, the IL-2 was to be discontinued.

i. You failed to withhold doses of IL-2 according to the requirements defined in protocol Table 1.

a. Subjects —— experienced hypotension that required therapy. These are Grade 3 adverse events that, according to protocol Table 1 and Appendix 1, required you to withhold subsequent IL-2 doses until the adverse event resolved. Instead, you continued IL-2 administration at reduced doses when the hypotension did not resolve. See item 2.C.ii below.

b. Furthermore, you administered a 15th dose of IL-2 even though Subject —— experienced Grade 4 hypocalcemia after the 14th dose. The blood sample drawn at 5:20 a.m. on 4/19/00 revealed a calcium level of 4.9 milligrams/deciliter, yet another dose of IL-2 was administered at 8:05 a.m. the same day. According to Appendix 1 to the protocol, this is a Grade 4 adverse event that should have resulted in discontinuation of IL-2.

ii. You reduced the dose of IL-2 for several subjects in violation of the protocol. The protocol did not permit the reduction of IL-2 to manage the toxic adverse events associated with IL-2. The following subjects are examples of IL-2 dose reductions:

a. Subjects —— one-half dose, one-quarter dose, and one-eighth dose.

b. Subjects —— one-half dose and one-quarter dose.

c. Subjects —— and —— one-half dose.
In your response letter dated January 11, 2002, your attorney explains "the protocol did not explicitly preclude IL-2 dose reduction." This statement is incorrect. Protocol section 8.4 states "the dose of IL-2 being administered is 360,000 IU/kg...." Table 1 defined the circumstances in which the dose of IL-2 could be modified and identifies only two options: keeping the same dose (designated by "-"), or skipping a dose (designated by "Hold"). Table 1 does not permit dose reductions.

Your response claims that from your "extensive experience in the administration of IL-2" you knew "that achieving maximum benefit from the administration of the drug, involves close monitoring of side-effects, and reduction of dosage when evidence of toxicity appears." However, your protocol had no provision for reducing the dose of IL-2, only the options of completely discontinuing (the "hold" option) IL-2 or continuing to administer the protocol-specified dosage. If you determined that the requirements in Table 1 were inadequate to manage IL-2 toxicity, then you should have submitted protocol amendments for Institutional Review Board (IRB) and FDA review to permit you to continue to administer the IL-2 at a reduced dose under defined circumstances. In the absence of an approved protocol amendment, you were not permitted to reduce the dose of IL-2 and continue to administer it in this study. Your response letter acknowledges that you should have amended the protocol to include IL-2 dose reductions.

D. You did not record the tumor measurement each time you administered the investigational drug to Subject——— as required by protocol 1995-318 sections 4 and 11.1. You did not measure the tumor on 7/14/99 and 8/11/99. These measurements were required to determine efficacy of the study.

E. You did not measure the vital signs for Subject——— in protocol 1995-318 before and after the first injection, and after the second injection. Protocol section 8.1 and Appendix 1 require you to measure vital signs "prior to injection and once during the hour for two hours after injection, or more frequently as needed." This was an important measurement to monitor the safety of the subject, especially for the first injection of the investigational product.

3. You failed to assure that the Institutional Review Board (IRB) would be responsible for the initial and continuing review and approval of the clinical studies prior to treatment of human subjects and prior to implementing changes. [21 §§ 312.66 and 56.103(a)].

You failed to submit a Phase II protocol to succeed protocol 1990-489. In a memorandum dated 3/17/95, the IRB informed you that a separate protocol was
required before you initiated a Phase II study. The IRB requested that you "submit a new study application, with protocol including data on toxicity and results of the initial study...." Furthermore, the IRB requested that you review the informed consent to "make it suitable" for a Phase II study. You replied to the IRB in a memorandum dated 4/18/95, in which you confirmed that you would submit a separate protocol for a Phase II study. You failed to do so. During the inspection you stated that you did not write a new protocol for the Phase II portion of the study. Furthermore, you reported to FDA that as of 7/27/2000, you had enrolled 34 subjects in the "Phase II" clinical trial referred to in study 1990-489. You informed the University of Michigan that you enrolled "more than 40" subjects into the Phase II study.

In your response letter dated January 11, 2002, your attorney admits that sometime after 7/17/97, you "commenced the phase II study in metastatic renal cell cancer and began accruing patients into this study." The IRB-approved protocol 1990-489 was designed to limit enrollment to "ten to fifteen patients with each malignancy..." (melanoma, renal cell, and colorectal carcinomas). Your response does not state why you never submitted the "Phase II" study protocol to the IRB as you had assured you would.

4. You failed to maintain adequate records of the disposition of investigational drugs. [21 CFR § 312.62(a)].

There are no study drug accountability records for studies 1995-243 and 1997-064. The University of Michigan Investigational Drug Pharmacy did not receive or dispense any drugs for either study. During the inspection you stated that you do not have any test article accountability records. According to records provided by your institution, you administered study drugs to five subjects under protocol 1995-243 and 28 subjects under protocol 1997-064.


5. You failed to maintain adequate and accurate case histories of individuals treated with investigational drugs. [21 CFR § 312.62(b)].

You were unable to provide copies of consent forms signed by some subjects enrolled in study 1990-489. No signed informed consent document was found in the medical charts or study records for Subjects and . This is not a complete list of subjects for whom you were unable to provide copies of signed informed consent forms.

In your response letter dated January 11, 2002, your attorney explains that the signed consent forms for Subjects and are lost. Your response also states that you believe that you obtained consent forms from all subjects who received the tumor vaccine and that the missing records were
misfiled or discarded by the University Clinical Trials Office (CTO) because "that department could not identify the patient to whom the document pertained and disposed of the document." However, without evidence to support it, this argument is facially implausible: the approved consent form for each protocol clearly lists the clinical investigator(s), the subject's name, and the name of one or more other University personnel to contact if the subject had any questions.

This letter is not intended to be an all-inclusive list of deficiencies with your clinical studies of investigational drugs.

On your behalf, your attorney states on page 13 of the January 11, 2002 response letter that you trust that the educational program being imposed by the University of Michigan will "...remedy the issues that underlay any unintentional regulatory violations on Dr. Chang's part, and will address any residual concerns that the agency may have with respect to Dr. Chang's ability in the future to conduct clinical trials that fully satisfy all regulatory requirements." Your response, and the educational program imposed by the University of Michigan, have not alleviated our concerns.

On the basis of the violations listed above, FDA asserts that you have repeatedly or deliberately failed to comply with the cited regulations, and it proposes that you be disqualified as a clinical investigator. You may reply to the above stated issues, including an explanation of why you should remain eligible to receive investigational drugs and not be disqualified as a clinical investigator, in a written response or at an informal conference in my office. This procedure is provided for by regulation 21 CFR 312.70(a).

Within fifteen (15) days of receipt of this letter, please write me to arrange a conference time or to indicate your intent to respond in writing. Your written response must be forwarded within thirty (30) days of receipt of this letter. Your reply should be sent to:

Mr. Steven A. Masiello, Director
Office of Compliance and Biologics Quality, HFM-600
Center for Biologics Evaluation and Research
Food and Drug Administration
1401 Rockville Pike
Rockville, Maryland 20852-1448

Should you request an informal conference, we ask that you provide us with a full and complete explanation of the above listed violations. You should bring with you all pertinent documents, and you may be accompanied by a representative. Although the conference is informal, a transcript will be prepared. If you choose to proceed in this manner, we plan to hold such a conference within 30 days of your request.
At any time during this administrative process, you may enter into a consent agreement with FDA regarding your future use of investigational products. Such an agreement would terminate this disqualification proceeding. Enclosed you will find a proposed agreement between you and FDA.

The Center will carefully consider any oral or written response. If your explanation is accepted by the Center, the disqualification process will be terminated. If your written or oral responses to our allegations are unsatisfactory, or we cannot come to terms on a consent agreement, or you do not respond to this notice, you will be offered the opportunity to request a regulatory hearing before FDA, pursuant to 21 CFR Part 16 (available at the Internet address identified on page 1 of this letter) and 21 CFR 312.70. Such a hearing will determine whether or not you will remain entitled to receive investigational products. You should be aware that neither entry into a consent agreement nor pursuit of a hearing precludes the possibility of a corollary judicial proceeding or administrative remedy concerning these violations.

Sincerely,

[Signature]

Steven A. Masiello
Director
Office of Compliance and Biologics Quality
Center for Biologics Evaluation and Research

Enclosure:
Proposed consent agreement

cc: Arthur Y. Tsien, Esq.
Olsson, Frank, and Weeda, P.C.
Suite 400
1400 Sixteenth Street, N.W.
Washington, DC 20036-2220